Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 105.45B |
| Enterprise value | 97.63B |
| Trailing P/E | 28.26 |
| Forward P/E | 21.19 |
| PEG ratio (5-yr expected) | 1.54 |
| Price/sales (ttm) | 8.33 |
| Price/book (mrq) | 3.91 |
| Enterprise value/revenue | 7.45 |
| Enterprise value/EBITDA | 21.46 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.14 |
| 52-week change 3 | 24.66% |
| S&P500 52-week change 3 | 22.38% |
| 52-week high 3 | 998.33 |
| 52-week low 3 | 684.81 |
| 50-day moving average 3 | 944.28 |
| 200-day moving average 3 | 867.66 |
Share statistics
| Avg vol (3-month) 3 | 472.84k |
| Avg vol (10-day) 3 | 532.48k |
| Shares outstanding 5 | 108.37M |
| Implied shares outstanding 6 | 110.19M |
| Float 8 | 105.39M |
| % held by insiders 1 | 1.69% |
| % held by institutions 1 | 89.00% |
| Shares short (15 Apr 2024) 4 | 1.39M |
| Short ratio (15 Apr 2024) 4 | 3.05 |
| Short % of float (15 Apr 2024) 4 | 1.50% |
| Short % of shares outstanding (15 Apr 2024) 4 | 1.26% |
| Shares short (prior month 15 Mar 2024) 4 | 1.39M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 29.45% |
| Operating margin (ttm) | 24.12% |
Management effectiveness
| Return on assets (ttm) | 7.74% |
| Return on equity (ttm) | 15.28% |
Income statement
| Revenue (ttm) | 13.1B |
| Revenue per share (ttm) | 122.57 |
| Quarterly revenue growth (yoy) | -0.50% |
| Gross profit (ttm) | N/A |
| EBITDA | 4.42B |
| Net income avi to common (ttm) | 3.86B |
| Diluted EPS (ttm) | 33.88 |
| Quarterly earnings growth (yoy) | -11.70% |
Balance sheet
| Total cash (mrq) | 10.52B |
| Total cash per share (mrq) | 95.47 |
| Total debt (mrq) | 2.7B |
| Total debt/equity (mrq) | 10.02% |
| Current ratio (mrq) | 5.27 |
| Book value per share (mrq) | 244.93 |
Cash flow statement
| Operating cash flow (ttm) | 4.74B |
| Levered free cash flow (ttm) | 3.03B |
© 2024 Yahoo. All rights reserved.